These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 31991007

  • 1. A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.
    Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T.
    J Bone Miner Res; 2020 Jul; 35(7):1207-1215. PubMed ID: 31991007
    [Abstract] [Full Text] [Related]

  • 2. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD.
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
    Clifton Goldney D, Pelegrin C, Jerkovich F, Longobardi V, Gonzalez Rodriguez E, Zanchetta MB.
    Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
    [Abstract] [Full Text] [Related]

  • 6. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
    Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P.
    J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
    Everts-Graber J, Lehmann T.
    J Clin Densitom; 2022 Dec; 25(3):293-298. PubMed ID: 35450795
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
    Horne AM, Mihov B, Reid IR.
    Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
    Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, Papatheodorou A, Makras P.
    Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
    Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP.
    J Bone Miner Res; 2018 Feb; 33(2):190-198. PubMed ID: 29105841
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.
    Everts-Graber J, Reichenbach S, Gahl B, Häuselmann H, Ziswiler HR, Studer U, Lehmann T.
    Bone; 2022 Oct; 163():116498. PubMed ID: 35882310
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.